Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.
Follow Brielle on Twitter @Brielle_Benyon.
FDA Approves CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma
May 2nd 2018The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) – a CAR-T cell therapy – for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).
Read More
Ovarian Cancer Expert Offers Hope Against 'Silent Killer' Stereotype
April 28th 2018CURE sat down with Richard Boulay, M.D., at the 2018 National Ovarian Cancer Coalition to discuss exciting updates in ovarian cancer, as well as what advice he would offer to patients and caregivers who may be feeling overwhelmed.
Read More
Combination Improves Responses, Misses Survival Endpoint in Bladder Cancer Trial
April 25th 2018The combination use of Cyramza (ramucirumab) plus docetaxel showed improvements in objective response rate (ORR) and a positive trend in overall survival (OS) among patients with advanced bladder cancer, according to additional results from the phase 3 RANGE trial.
Read More
FDA Approves First Assay to Identify Rubraca Benefit Among Women with Ovarian Cancer
April 24th 2018The Food and Drug Administration (FDA) approved a next-generation sequencing (NGS) companion diagnostic assay that can detect BRCA1/2 genetic mutations, as well as the percentage of genomic loss of heterozygosity (LOH) in patients with ovarian cancer.
Read More
Pre-Surgical Immunotherapy Identifies Potential Benefit, Risk of Recurrence in Melanoma
April 19th 2018For patients with melanoma, administration of a PD-1 checkpoint blockade therapy in the neoadjuvant setting – meaning it was given before the main treatment – could result in improved outcomes and better insight to patient responses.
Read More
Frontline Opdivo-Yervoy Combo Shows Promise in Advanced Non-Small Cell Lung Cancer
April 17th 2018Most recently, the dynamic duo of Yervoy (ipilimumab) plus Opdivo (nivolumab) – both checkpoint inhibitors – extended average progression-free survival (PFS) rates more than three times than standard-of-care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB).
Read More
FDA Approves Immunotherapy Duo for Kidney Cancer
April 16th 2018The Food and Drug Administration (FDA) approved the immunotherapy combination of Yervoy (ipilimumab) plus Opdivo (nivolumab) to treat patients with intermediate- or poor-risk advanced renal cell carcinoma in the frontline setting.
Read More
FDA Approves Rubraca for Maintenance Ovarian Cancer Treatment
April 6th 2018The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the company that manufactures the drug.
Read More
Opdivo Combination Granted Priority Review to Treat Metastatic Colorectal Cancer
March 27th 2018The Food and Drug Administration (FDA) granted priority review to the combination use of Opdivo (nivolumab) and Yervoy (ipilimumab) to treat a subgroup of patients with metastatic colorectal cancer.
Read More
Survivorship Planning Should Start at Diagnosis
March 27th 2018Many aspects of going through cancer can be overwhelming or difficult to navigate, so it is important that survivors have resources to help them navigate from the point of diagnosis to beyond the moment when their treatment ends.
Read More
Chemotherapy Could Make a Comeback, But Only Clinical Trials Will Tell
March 23rd 2018Chemotherapy can aid in making a tumor “hot” – meaning that it attracts tumor-infiltrating lymphocytes (TILs), which are linked to killing tumor cells – priming it to respond better to immunotherapy treatment.
Read More